Bristol Myers Squibb (BMY) Stock
Diversified biopharmaceutical company with oncology and immunology medicines. Here's the price, business snapshot, and what's worth knowing about Bristol Myers Squibb in October 2026.
Bristol-Myers Squibb (BMY) is a large, diversified biopharmaceutical company with a market cap of about $90.7bn. Investors should know it combines an established portfolio of marketed medicines—particularly in oncology, haematology and immunology—with a deep pipeline and substantial R&D spending. Key revenue drivers include immuno‑oncology and speciality medicines, though some legacy products face generic competition as patents expire. The 2019 Celgene acquisition broadened product mix but increased leverage, making cash generation and debt management important considerations. Regulatory outcomes, trial results and competitive approvals can move the share price materially. BMY typically pays a dividend, which may appeal to income‑minded investors, but dividends and share values can fall. This summary is for educational purposes only and not personalised advice; always consider your risk tolerance and do further research or speak to a financial adviser before investing.
Why It’s Moving
BMY Stock Faces Valuation Scrutiny Despite Camzyos Expansion and Dividend Streak
- The U.S. FDA approved an expanded indication for Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients, broadening its addressable market.
- Management raised 2026 revenue guidance to $49 billion–$50 billion following a 15% increase in Growth Portfolio sales during the second quarter, signaling progress in replacing legacy drug revenue.
- Despite trading at a discounted valuation relative to peers like AbbVie and Eli Lilly, concerns persist regarding the sustainability of the dividend once major patents expire in 2027.
BMY Stock Faces Valuation Scrutiny Despite Camzyos Expansion and Dividend Streak
- The U.S. FDA approved an expanded indication for Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients, broadening its addressable market.
- Management raised 2026 revenue guidance to $49 billion–$50 billion following a 15% increase in Growth Portfolio sales during the second quarter, signaling progress in replacing legacy drug revenue.
- Despite trading at a discounted valuation relative to peers like AbbVie and Eli Lilly, concerns persist regarding the sustainability of the dividend once major patents expire in 2027.
Sixth Month Growth Performance
When is the next earnings date for Bristol Myers Squibb (BMY)?
Bristol-Myers Squibb has a confirmed upcoming earnings report scheduled for 2026-10-29. This release will cover the company's third-quarter 2026 financial results. The timing aligns with historical patterns, as previous reports occurred in late October and early February.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Bristol Myers Squibb's stock with a target price of $61.88, indicating growth potential.
Financial Health
Bristol Myers Squibb is generating strong revenue and profits, showing solid cash flow performance.
Dividend
Bristol Myers Squibb's dividend yield of 3.07% offers a modest return for dividend-seeking investors. If you invested $1000 you would be paid $30.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Oncology-led revenue engine
BMY’s oncology and haematology drugs drive sales and headline growth, though trial outcomes and competition can cause swings in performance.
Pipeline and R&D programme
A substantial pipeline offers upside if trials succeed, but R&D failures and regulatory delays are common and can affect value.
Cash flow and balance
Established medicines and partnerships support cash flow, yet patent cliffs and post-acquisition debt make balance-sheet management important.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
